{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-049802","form_type":"8-K","ticker":"ATYR","cik":"0001339970","company_name":"aTYR PHARMA INC","filed_at":"2023-09-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.658746+00:00","generated_at":"2026-06-10T08:36:56.393524+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"aTyr Pharma initiates Phase 2 EFZO-CONNECT study of efzofitimod in SSc-ILD","bullets":["EFZO-CONNECT is a randomized, double-blind, placebo-controlled Phase 2 proof-of-concept study in systemic sclerosis-associated ILD.","Study enrolls 25 patients across multiple US centers; 28-week treatment with monthly IV doses of efzofitimod (270 mg or 450 mg) or placebo.","Primary objective: evaluate efficacy of efzofitimod on pulmonary, cutaneous, and systemic manifestations in SSc-ILD."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-049802","json":"https://secwatch.observer/filing/0000950170-23-049802.json","markdown":"https://secwatch.observer/filing/0000950170-23-049802.md","text":"https://secwatch.observer/filing/0000950170-23-049802.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1339970/000095017023049802/0000950170-23-049802-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1339970/000095017023049802/life-20230926.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T08:36:56.393524+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}